Document is current
Any future updates will be listed below
-
Authors
Schlabitz, Sophie https://orcid.org/0000-0002-8918-6715
Doerrfuss, Jakob I. https://orcid.org/0000-0002-8682-0215
Hebel, Jonas M. https://orcid.org/0000-0002-2414-0441
Körtvélyessy, Péter https://orcid.org/0000-0003-1262-6169
Holtkamp, Martin https://orcid.org/0000-0003-2258-1670
Gaus, Verena https://orcid.org/0000-0001-6003-936X
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 3 February 2026
Revised: 19 March 2026
Accepted: 23 March 2026
First Online: 2 April 2026
Declarations
:
: Sophie Schlabitz, Jonas Hebel and Péter Körtvélyessy report no conflicts of interest. Jakob Dörrfuß reports personal fees from Eisai within the last 3 years, unrelated to the contents of the article. Martin Holtkamp received speaker’s honoraria within the last 3 years from Angelini, Bial, Danone, Desitin, Eisai, Jazz Pharma, Neuraxpharm, and UCB, unrelated to the contents of the article. Verena Gaus received a speaker’s honorarium (podcast recording) from Angelini Pharma within the last 3 years, unrelated to the contents of the article.
: The study was approved by the Ethics Committee of Charité – Universitätsmedizin Berlin (Application No. EA2/263/23) and conducted in accordance with the World Medical Association Declaration of Helsinki. Due to the retrospective study design and the use of pseudonymized clinical data, the requirement for written informed consent was waived by the Ethics Committee. Data protection regulations were strictly observed, and patient confidentiality was ensured.
